Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR3 - TACC3 FGFR3 over exp |
Therapy | Futibatinib |
Indication/Tumor Type | urinary bladder cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 - TACC3 FGFR3 over exp | urinary bladder cancer | sensitive | Futibatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Futibatinib (TAS-120) treatment led to inhibition of cell proliferation in bladder cancer cell lines with FGFR3 overexpression and harboring FGFR3-TACC3 in culture, and led to inhibition of tumor growth in a cell line xenograft model (PMID: 32973082). | 32973082 |
PubMed Id | Reference Title | Details |
---|---|---|
(32973082) | Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. | Full reference... |